Elizabeth Hellström
YOU?
Author Swipe
P-364. Efficacy and Safety by Sex Assigned at Birth After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1 Open
Background In two Phase 3 studies, switching to doravirine/islatravir (DOR/ISL, 100 mg/0.25 mg), an investigational once-daily regimen for HIV treatment, was non-inferior for efficacy with a safety profile comparable to continuing baseline…
View article: A novel and safe SmartCap® SC101 to develop the COVID-19 mRNA vaccine STP2104 inducing potent immune responses in humans
A novel and safe SmartCap® SC101 to develop the COVID-19 mRNA vaccine STP2104 inducing potent immune responses in humans Open
We have developed a 5′-capping library screening (CLS) method using over 30 different novel cap analogues. The optimal 5′-cap for the coronavirus disease 2019 (COVID-19) mRNA vaccine STP2104 was selected and applied. This is the first repo…
BCG Revaccination for the Prevention of <i>Mycobacterium tuberculosis</i> Infection Open
BCG revaccination in QFT-test negative, HIV-negative adolescents did not provide protection from sustained M. tuberculosis infection. (Funded by the Gates Foundation; ClinicalTrials.gov number NCT04152161.).
View article: Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg
Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg Open
Introduction Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was efficacious and well tolerated in children/adolescents with HIV (aged ≥6 years, weighing ≥25 kg) in a Phase 2/3 study. Here, we report data from child…
Final Analysis of a Trial of M72/AS01 <sub>E</sub> Vaccine to Prevent Tuberculosis Open
Among adults infected with M. tuberculosis, vaccination with M72/AS01E elicited an immune response and provided protection against progression to pulmonary tuberculosis disease for at least 3 years. (Funded by GlaxoSmithKline Biologicals a…
120. A Randomized Double-blind Trial Assessing the Efficacy of M72/AS01E Vaccine Against Pulmonary Tuberculosis Disease in Adults With Latent Mycobacterium tuberculosis Infection Open
Background An effective tuberculosis (TB) vaccine is urgently needed to support the End TB Strategy to reduce the number of new TB cases by 80% by 2030. M72/AS01E candidate vaccine is an adjuvanted recombinant fusion protein derived from M…
Phase 2b Controlled Trial of M72/AS01 <sub>E</sub> Vaccine to Prevent Tuberculosis Open
M72/AS01E provided 54.0% protection for M. tuberculosis-infected adults against active pulmonary tuberculosis disease, without evident safety concerns. (Funded by GlaxoSmithKline Biologicals and Aeras; ClinicalTrials.gov number, NCT0175559…
C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial Open
ClinicalTrials.gov NCT01642888. EudraCT 2011-005078-40.
Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa Open
ClinicalTrials.gov NCT01071174.